Citations

Clear

390 citation(s) found for "Loftus, E".

Vedolizumab Drug Level Correlation With Clinical Remission, Biomarker Normalization, and Mucosal Healing in Inflammatory Bowel Disease
Al‐Bawardy, Badr , Ramos, Guilherme Piovezani , Jenkins, Sarah M. , Park, Sang Hyoung , Schoenoff, Shayla, Bruining, David H. , Papadakis, Konstantinos A. , Raffals, Laura E. , Tremaine, William J., Loftus, Edward V. , Aniwan, Satimai , Schoenoff, Shayla A, Raffals, Laura, Loftus, Edward V , Ramos, Guilherme P , Willrich, Maria Alice V.

Mayo Clinic

Inflammatory Bowel Diseases | August 24, 2018 | Volume: 25 | Issue: 3 | Pages: 580-586

10.1093/ibd/izy272 | PMID 30165638 Get It

Abstract 3462: EGFRvIII-Stat5 signaling enhances glioblastoma cell invasion
Roos, Alison , Peng, Sen, Inge, Landon J. , Tuncali, Serdar, Pineda, Michael , Millard, Nghia , Winkles, Jeffrey A. , Loftus, Joseph C. , Tran, Nhan L. , Dhruv, Harshil , Tran, Nhan L

Mayo Clinic

Cancer Research | August 17, 2018 | Volume: 78 | Issue: 13_Supplement | Pages: 3462-3462

10.1158/1538-7445.am2018-3462 Get It

Abstract Glioblastoma Multiforme (GBM) is the most common malignant brain tumor in adults. Most GBM patients succumb to the disease less than one-year post diagnosis due to the highly invasive nature of the tumor, which prevents complete surgical resection and gives rise to tumor recurrence. The invasive phenotype also confers radio and chemoresistant properties to the tumor cells; therefore, there is a need to develop new therapeutics that target drivers of GBM invasion. Amplification of EGFR is observed in over 50% of GBM tumors, of which half concurrently overexpress the variant EGFRvIII, and expression of both receptors confers a worse prognosis. EGFR and EGFRvIII cooperate to promote tumor progression and invasion, in part, through activation of the Stat-signaling pathway. Here we report that EGFRvIII activates Stat5 and GBM invasion, in part, by inducing the expression of a previously established mediator of glioma cell invasion and survival, fibroblast growth factor-inducible 14 (Fn14). EGFRvIII-mediated induction of Fn14 expression is dependent upon Stat5 and requires activation of Src, whereas EGFR regulation of Fn14 is dependent upon MEK/ERK-Stat3 activation. Notably, treatment of EGFRvIII expressing GBM cells with the FDA approved Stat5 inhibitor pimozide blocked Stat5 phosphorylation, Fn14 expression, and cell migration. Since EGFR inhibitors display limited therapeutic efficacy in GBM patients, we hypothesize that the EGFRvIII-Stat5-Fn14 signaling pathway represents a node of vulnerability in the invasive GB cell population and that targeting critical effectors in this pathway will limit GBM tumor dispersion, mitigate therapeutic resistance, and increase survival. Citation Format: Alison Roos, Harshil D. Dhruv, Sen Peng, Landon J. Inge, Serdar Tuncali, Michael Pineda, Nghia Millard, Jeffrey A. Winkles, Joseph C. Loftus, Nhan L. Tran. EGFRvIII-Stat5 signaling enhances glioblastoma cell invasion [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 3462.
Editorial: biologic therapies for primary sclerosing cholangitis—more disappointment than promise? Authors’ reply
Tse, Chung Sang , Loftus, Edward V. , Raffals, Laura E. , Gossard, Andrea A., Lightner, Amy L. , Tse, C S , Lightner, A L , Loftus, Edward V

Mayo Clinic

Alimentary Pharmacology & Therapeutics | August 10, 2018 | Volume: 48 | Issue: 5 | Pages: 578-579

10.1111/apt.14907 | PMID 30156321 Get It

Linked ContentThis article is linked to Tse et al and Ma and Kotze paper. To view these articles visit https://doi.org/10.1111/apt.14829 and https://doi.org/10.1111/apt.14858.
Vedolizumab and early postoperative complications in nonintestinal surgery: a case-matched analysis
Kotze, Paulo Gustavo , McKenna, Nicholas P. , Almutairdi, Abdulelah , Kaplan, Gilaad G. , Raffals, Laura E. , Loftus, Edward V. , Mckenna, Nicholas, Loftus, Edward V , Kotze, Paulo G , Kaplan, Gilaad G , Ma, Christopher , Panaccione, Remo , Lightner, Amy L. , McKenna, Nicholas P

Mayo Clinic

Therapeutic Advances in Gastroenterology | June 21, 2018 | Volume: 11 | Issue: No issue available | Pages: No page available

10.1177/1756284818783614 | PMID 29977340 Get It

Background: Vedolizumab (VDZ) is a gut-specific α4-β7 integrin antagonist that has demonstrated efficacy in Crohn’s disease (CD) and ulcerative colitis (UC). The safety of VDZ in the perioperative period remains unclear. The aim of this study was to evaluate postoperative complications and perioperative safety in VDZ-treated patients undergoing nonintestinal operations. Methods: A case-matched study was performed at two inflammatory bowel disease (IBD) referral centers. Adult patients with CD and UC who underwent a nonintestinal surgical procedure during treatment with VDZ were included. Patients who had their last VDZ infusion up to 12 weeks before the procedure were considered exposed and were matched in a 1:1 ratio to patients without VDZ therapy, according to type of surgical procedure, age, and sex. The primary outcome was overall risk of early postoperative infectious complications (up to 30 days after surgery), readmissions, reoperations, surgical site infections, and other infections. The VDZ and control groups were subsequently compared using the Pearson χ2 test and Wilcoxon rank sum. Results: We identified 34 patients treated with VDZ who underwent 36 nonintestinal surgical procedures. These patients were matched with 36 control procedures. Postoperative complications were not different between the VDZ-treated and control cohorts for all outcomes analyzed: infectious complications occurred in 14% versus 8% ( p = 0.45), superficial surgical site infections 6% versus 0% ( p = 0.15), reoperations 6% versus 3% ( p = 0.56) and readmissions 11% versus 6% ( p = 0.37). Conclusions: VDZ-treated patients with IBD undergoing nonintestinal procedures did not have an increased risk of overall postoperative infections or other complications compared with matched controls.
Effects of vedolizumab, adalimumab and infliximab on biliary inflammation in individuals with primary sclerosing cholangitis and inflammatory bowel disease
Tse, Chung Sang , Loftus, Edward V. , Raffals, Laura E. , Gossard, Andrea A., Lightner, Amy L. , Tse, C S , Lightner, A L , Loftus, Edward V

Mayo Clinic

Alimentary Pharmacology & Therapeutics | May 29, 2018 | Volume: 48 | Issue: 2 | Pages: 190-195

10.1111/apt.14829 | PMID 29808485 Get It

SummaryBackgroundPrimary sclerosing cholangitis (PSC) is a chronic, progressive cholestatic biliary disease associated with inflammatory bowel disease (IBD) with no known cure.AimTo evaluate the effect of biological therapies on PSC progression in IBD patients.MethodsWe performed a retrospective cohort study of 88 cases (75 unique patients with 12 patients treated >1 biologics) of IBD (48 ulcerative colitis, 24 Crohn's disease and 3 indeterminate colitis) with concomitant PSC who received biological therapy (42 infliximab, 19 adalimumab, 27 vedolizumab) between June 2002 and October 2017. Hepatic biochemistries were compared using the paired t‐test (patients served as their own controls) ≤3 months before and 6‐8 and 12‐14 months after biological initiation. Radiographic information of biliary stenosis and liver fibrosis were obtained via abdominal ultrasound, abdominal magnetic resonance imaging and magnetic resonance elastography.ResultsUse of adalimumab was associated with a significant decrease in alkaline phosphatase (ALP) after 6‐8 months (P = 0.03; mean change −70 U/L, standard deviation [SD] 88 U/L) compared to vedolizumab (mean change +50 U/L, SD 142 U/L) or infliximab (mean change +37 U/L, SD 183 U/L) but the change was not significant after 12‐14 months (P = 0.24). No significant decreases were observed with AST, ALT, total or direct bilirubin, elastography score or radiographic imaging of biliary tree dilation/strictures with any biological therapy after 6‐8 or 12‐14 months.ConclusionsCurrent evidence suggests that biological therapies used for the treatment of IBD are not effective treatments for PSC. Further study is needed to elucidate any potential beneficial effect of adalimumab on PSC.
A Phase 2, Randomized, Placebo-Controlled Study Evaluating Matrix Metalloproteinase-9 Inhibitor, Andecaliximab, in Patients With Moderately to Severely Active Crohn’s Disease
Friedenberg, Keith, Younes, Ziad , Seidler, Ursula , Bhandari, Bal Raj, Wang, Ke , Wendt, Emily, McKevitt, Matt, Zhao, Sally, Sundy, John S., Lee, Scott D. , Loftus, Edward V. , Loftus, Edward V , Schreiber, Stefan , Siegel, Corey A

Mayo Clinic

Journal of Crohn's and Colitis | May 28, 2018 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/ecco-jcc/jjy070 | PMID 29846530 Get It

Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease
Shmidt, Eugenia , Kochhar, Gursimran , Hartke, Justin, Meserve, Joseph , Chaudrey, Khadija, Koliani‐Pace, Jenna L., Hirten, Robert , Faleck, David M. , Barocas, Morris, Luo, Michelle , Lasch, Karen, Boland, Brigid S. , Singh, Siddharth , Casteele, Niels Vande , Sagi, Sashidhar, Fischer, Monika , Chang, Shannon, Bohm, Matthew , Lukin, Dana J. , Sultan, Keith , Hudesman, David , Kane, Sunanda V. , Loftus, Edward V. , Sandborn, William J. , Shen, Bo , Dulai, Parambir S. , Chang, Sam S. , Vande Casteele, N , Loftus, Edward V , Chilukuri, Prianka , Sagi, Sashidhar , Chang, Shannon, Swaminath, Arun C. , Gupta, Nitin Kumar , Siegel, Corey A , Sands, Bruce E , Colombel, Jean‐Frédéric , Chang, Shannon

Mayo Clinic

Inflammatory Bowel Diseases | May 18, 2018 | Volume: 24 | Issue: 11 | Pages: 2461-2467

10.1093/ibd/izy171 | PMID 29788240 Get It

Abstract Background We quantified loss of response (LOR) to vedolizumab (VDZ) in clinical practice and assessed the effectiveness of VDZ dose intensification for managing LOR. Methods Retrospective review (May 2014–December 2016) of a prospectively maintained inflammatory bowel disease (IBD) registry. Kaplan-Meier estimates were used to determine rates of LOR to VDZ . Independent predictors of LOR were identified using univariate and multivariable Cox proportional hazard regression. Success of recapturing response (>50% reduction in symptoms from baseline) and remission (complete resolution of symptoms) after dose intensification was quantified. Results Cumulative rates for VDZ LOR were 20% at 6 months and 35% at 12 months, with slightly lower rates in Crohn’s disease than in ulcerative colitis (6 months 15% vs 18% and 12 months 30% vs 39%, P = 0.03). On multivariable analysis, LOR to a tumor necrosis factor (TNF) antagonist before VDZ use was associated with an increased risk for LOR to VDZ [hazard ratio (HR) 1.93; 95% confidence interval (CI) 1.25–2.97] in all patients. For Crohn’s disease patients specifically, higher baseline C-reactive protein concentration was associated with increased risk for LOR to VDZ (HR 1.01 per mg/dL increase, 95% CI 1.01–1.02). Shortening of VDZ infusion interval from 8 to every 4 or 6 weeks recaptured response in 49% and remission in 18% of patients. Conclusions LOR to a TNF antagonist before VDZ use and higher baseline C-reactive protein are important predictors of VDZ LOR. Treatment response can be recaptured in almost half of these patients with VDZ infusion interval shortening.
EGFRvIII–Stat5 Signaling Enhances Glioblastoma Cell Migration and Survival
Roos, Alison , Peng, Sen, Inge, Landon J. , Tuncali, Serdar, Pineda, Michael , Millard, Nghia , Mayo, Zachary, Eschbacher, Jennifer , Loftus, Joseph C. , Winkles, Jeffrey A. , Tran, Nhan L. , Pineda, Michael , Winkles, Jeffrey A , Dhruv, Harshil , Tran, Nhan L

Mayo Clinic

Molecular Cancer Research | May 3, 2018 | Volume: 16 | Issue: 7 | Pages: 1185-1195

10.1158/1541-7786.mcr-18-0125 | PMID 29724813 Get It

Abstract Glioblastoma multiforme (GBM) is the most common brain malignancies in adults. Most GBM patients succumb to the disease less than 1 year after diagnosis due to the highly invasive nature of the tumor, which prevents complete surgical resection and gives rise to tumor recurrence. The invasive phenotype also confers radioresistant and chemoresistant properties to the tumor cells; therefore, there is a critical need to develop new therapeutics that target drivers of GBM invasion. Amplification of EGFR is observed in over 50% of GBM tumors, of which half concurrently overexpress the variant EGFRvIII, and expression of both receptors confers a worse prognosis. EGFR and EGFRvIII cooperate to promote tumor progression and invasion, in part, through activation of the Stat signaling pathway. Here, it is reported that EGFRvIII activates Stat5 and GBM invasion by inducing the expression of a previously established mediator of glioma cell invasion and survival: fibroblast growth factor-inducible 14 (Fn14). EGFRvIII-mediated induction of Fn14 expression is Stat5 dependent and requires activation of Src, whereas EGFR regulation of Fn14 is dependent upon Src–MEK/ERK–Stat3 activation. Notably, treatment of EGFRvIII-expressing GBM cells with the FDA-approved Stat5 inhibitor pimozide blocked Stat5 phosphorylation, Fn14 expression, and cell migration and survival. Because EGFR inhibitors display limited therapeutic efficacy in GBM patients, the EGFRvIII–Stat5–Fn14 signaling pathway represents a node of vulnerability in the invasive GBM cell populations. Implications: Targeting critical effectors in the EGFRvIII–Stat5–Fn14 pathway may limit GBM tumor dispersion, mitigate therapeutic resistance, and increase survival. Mol Cancer Res; 16(7); 1185–95. ©2018 AACR.